Correction to: Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial

In the article by Lai et al, “Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial” which initially published online February 2, 2022 and which appeared in the March 2022 issue of the journal (Circ Cardiovasc Qual Outcomes. 2022;15: e007923. doi: 10.1161/CIRCOUTCOMES.121.007923), the following corrections are needed.

On page 3, in the Interventions section, the first sentence should be “Patients in the SXC group received three SXC capsules (0.5 g/capsule; Chengdu Kanghong Pharmaceutical Group, Co, Ltd, Chengdu, China), 3× a day for 8 weeks”, not “one SXC capsules (0.5 g/capsule), 3× a day for 8 weeks”.

On page 5, in the Other BP Outcomes section, in the sentence “Similar trends were observed for daytime and nighttime SDP/DBP”, SDP should be SBP.

The authors regret these errors.

These corrections have been made to the current version of the article, which is available at: https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.121.007923